Document is current
Any future updates will be listed below
-
Authors
Siekmeier, Peter J. https://orcid.org/0009-0006-6494-9794
Coyle, Joseph T. https://orcid.org/0000-0002-0702-1395
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K08 MH072771)
Eli Lilly and Co.
- License Information
-
More Information
Article History
Received: 11 January 2025
Revised: 22 July 2025
Accepted: 1 September 2025
First Online: 10 October 2025
Competing interests
: JTC is a co-founder of Waveform Biosciences (Cambridge, MA), which proposes using EEG patterns to predict responders to novel psychiatric drugs, and is a member of the Scientific Advisory Board of SyneuRx (New Taipei City, Taiwan), which is developing potential psychiatric drugs from nutraceuticals. PJS is a co-founder of Waveform Biosciences. JTC and PJS are co-inventors on patent applications PCT/US2020/49194, “Apparatuses and methods for identification and treatment of patients responsive to antipsychotic agent therapy” and PCT/US2020/49283, “Method of increasing cognitive function with glutamate receptor agonist”, which are related to this work.
